RVMD ▼ -0.2% - Revolution Medicines, Inc. $RVMD - Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 19-NOV-2026 06:05 PM ET